Human Papillomavirus and Factors Associated with Recurrence in Sinonasal Inverted Papillomas from Poland and Spain.

Autor: Fulla M; Department of Otorhinolaryngology, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. mfulla@bellvitgehospital.cat.; Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. mfulla@bellvitgehospital.cat., Szafarowski T; Department of Otorhinolaryngology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Warsaw, Poland., Frias-Gomez J; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - L'Hospitalet de Llobregat, Barcelona, Spain.; Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Quiros B; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - L'Hospitalet de Llobregat, Barcelona, Spain.; Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Clavero O; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - L'Hospitalet de Llobregat, Barcelona, Spain.; Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Gomà M; Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Department of Pathology, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain., Pavon MA; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - L'Hospitalet de Llobregat, Barcelona, Spain.; Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Jurek-Matusiak O; Department of Otorhinolaryngology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Warsaw, Poland., Lares HR; Department of Otorhinolaryngology, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Mañós M; Department of Otorhinolaryngology, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; University of Barcelona, Barcelona, Spain., Alemany L; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - L'Hospitalet de Llobregat, Barcelona, Spain.; Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain., Mena M; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - L'Hospitalet de Llobregat, Barcelona, Spain.; Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Gonzalez X; Department of Otorhinolaryngology, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Jazyk: angličtina
Zdroj: Head and neck pathology [Head Neck Pathol] 2020 Sep; Vol. 14 (3), pp. 758-767. Date of Electronic Publication: 2020 Jan 08.
DOI: 10.1007/s12105-019-01125-y
Abstrakt: Sinonasal inverted papilloma (SNIP) is a benign but locally aggressive tumor that has a tendency for recurrence and malignant transformation. The role of human papillomavirus (HPV) in SNIP is controversial. To determine the HPV-DNA prevalence and type distribution in SNIP in two different geographic areas and assess the association between SNIP recurrence and HPV infection, as well as additional potential etiologic factors. Two retrospective cohorts of SNIP patients from Poland and Spain were evaluated. Demographic, tobacco/alcohol use, clinical, and follow-up data were collected. All samples were subject to histopathologic evaluation, DNA quality control, and HPV-DNA detection by PCR. HPV-DNA positive samples and a random sample of HPV-DNA negative cases were further subject to p16 INK4a analysis. Proportional-hazards models were used to evaluate the risk of recurrence by selected variables. Seventy-nine SNIP patients (46 from Spain diagnosed between 1995 and 2014, and 33 from Poland diagnosed between 2012 and 2017) were included in the study. HPV-DNA was detected in four patients (5.1%), two from each region, and all four were positive for the HPV11 subtype. Seventeen patients (21.5%) experienced recurrence, with a median time to recurrence of 14 months. No association was identified between lesional HPV-DNA positivity, toxic habits, Krouse stage, or malignant transformation and a higher risk of recurrence. The low prevalence of HPV-DNA in SNIPs suggests that HPV is not a main etiology for development of these lesions. With a lack of association between the evaluated factors and recurrence, further research with larger number of patients and additional biomarkers is warranted to further understand predisposing risk factors.
Databáze: MEDLINE
Externí odkaz: